Sail Biomedicines is shrinking its crew for the second time this year. | Sail Biomedicines is shrinking its crew for the ...

Heartflow is once again looking for a path to go public, with a filing for a Nasdaq IPO. | The former Fierce Medtech Fierce ...

While the previous two deaths occurred in patients treated with Elevidys, the most recent patient was receiving one of ...

Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Kennedy Jr. has downplayed the effectiveness of the long-used vaccine and instead promoted the development of new treatments ...

The U.K. is establishing a new biosecurity center designed to improve research into potentially pandemic-causing pathogens ...

To secure the antibody, I-Mab is paying $1.8 million upfront to buy Bridge Health, to be followed by noncontingent quarterly ...

Abbott is doubling down on the structural heart space as it aims to gain ground in valve replacements following the recent ...

Artificial-intelligence-powered spine surgery developer Carlsmed is showing some backbone as it kicks off its IPO, with plans ...

Alphabet spinoff SandboxAQ is teaming up with iOncologi to build a new mRNA vaccine for a common and aggressive brain tumor ...

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...

Following two rounds of pipeline prioritizations in a year, Repare reaffirmed this morning that it is focused on a pair of ...